Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients. This study was conducted to identify optimal regimens of BLBLIs in these patients. A Monte Carlo simulati...

Full description

Bibliographic Details
Main Authors: Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Antibiotics
Subjects:
novel β-lactam/β-lactamase inhibitors
Gram-negative bacteria infection
critically ill patients
pharmacokinetics/pharmacodynamics
Monte Carlo simulations
Online Access:https://www.mdpi.com/2079-6382/10/8/993

Internet

https://www.mdpi.com/2079-6382/10/8/993

Similar Items